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Background: Analysis of the prescribing patterns of antipsychotic drugs can improve therapeutic outcomes. The
purpose of this study was to evaluate the prescribing pattern of antipsychotics and its conformance to international
treatment guidelines.
Methods: A cross sectional study at primary psychiatric centers was carried out. Patients’ medical files were used to
obtain demographic, medication and clinical information. International guidelines for schizophrenia were used to
create conformance indicators. All statistical analyses were conducted using Statistical Package for Social Sciences.
Results: 250 patients were included in this study. A total of 406 antipsychotic agents were used; 348 (85.7%) were
first generation antipsychotics (FGA). The prevalence of antipsychotic combination was 50.4% (n=126). There was
no significant difference in positive (p=0.3), negative (p=0.06) and psychopathology (p=0.5) scores of schizophrenia
symptoms among patients on monotherapy versus those on antipsychotic combination. Furthermore, no significant
difference was observed in the annual cost of antipsychotic monotherapy versus combination therapy. One
hundred and five patients (42%) were using optimum dose of (300 – 600 mg CPZeq) while the remaining were
using sub or supra therapeutic doses. Analysis showed that use of depot, use of anticholinergic agents and
increasing amount of total CPZeq were significant factors associated with antipsychotic combination.
Conclusions: This study indicated that antipsychotic prescribing was not in conformance with international
guidelines with respect to maintenance dose and combination therapy. Type of antipsychotic treatment regimen,
combination versus monotherapy, was not associated with better clinical or economic outcome.
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Schizophrenia is a devastating mental illness that im-
pairs mental and social functioning. The stigmatization
of people who have a mental illness adds to difficulties
in their daily life and increases the probability that those
patients will be offered services that are of inferior qual-
ity to their needs. In the Arab world, mental health ser-
vices are far away from optimum and there is a lack of
reliable epidemiological psychiatric data which does not
enable rational planning for future psychiatric services,
education and research [1,2].* Correspondence: waleedsweileh@yahoo.com
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reproduction in any medium, provided the orTo improve psychiatric services, a large number of
countries and organizations throughout the world have
developed their own guidelines for the treatment of schizo-
phrenia [3]. There are several major and well known guide-
lines/algorithms for the treatment of schizophrenia: the
American Psychiatric Association (APA) Practice Guideline
for the Treatment of Patients with Schizophrenia [4]; the
Schizophrenia Patient Outcomes Research Team (PORT)
treatment recommendations [5]; and the Texas Medication
Algorithm Project (TMAP) antipsychotic algorithm for
schizophrenia [6]. Additionally, recent studies such as the
Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE) [7], the Cost Utility of the Latest Antipsychotic
Drugs in Schizophrenia Study (CUtLASS) [8], and their
comparisons have shed more light on the Nationall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Sweileh et al. BMC Psychiatry 2013, 13:179 Page 2 of 8
http://www.biomedcentral.com/1471-244X/13/179Institute for Health and Clinical Excellence (NICE)
schizophrenia guideline from the United Kingdom [9].
Such guidelines generally acknowledge that there is a lack
of evidence to support the routine use of combined anti-
psychotics except when switching from one antipsychotic
to another or augmenting clozapine in treatment-resistant
illness [6,9,10]. Furthermore, there is a consensus among
most guidelines about the optimum maintenance dose for
treatment of schizophrenia.
The need to analyze the prescribing patterns of anti-
psychotic drugs is not to find blame but to identify areas
where regulatory policies can improve prescribing pat-
terns and outcomes. As Palestinian legislators and pol-
icy makers seek to tighten medication wastage, a study
of the prescribing pattern of antipsychotic drugs will
serve as a baseline data to help policy makers to imple-
ment protocols that are safe and cost effective in
Palestinian authority.
The current study draws a sample of patients with
schizophrenia to examine the antipsychotic prescribing
pattern and conformance of antipsychotic drug pre-
scribing with international guidelines. Particularly, fre-
quency of antipsychotic combination and maintenance
dose will be examined. Furthermore, factors associated
with antipsychotic combination, and the clinical and
economic impact of antipsychotic combination will be
investigated.
Methods
A cross sectional study was conducted between August
2011 and February 2012. The Palestinian territories,
where the study took place, comprise the West Bank,
Gaza Strip and East Jerusalem. This study was carried
out at the 4 governmental primary psychiatric healthcare
centers located in Nablus, Tulkaram, Jenin and Qalqilia
in northern West-Bank, Palestine.
The centers included in the study were those in
Nablus, Jenin, Tulkaram, and Qalqilia. Patients who ful-
filled the following criteria were invited to participate: 1)
their age was above 16 years old, 2) they were diagnosed
with schizophrenia as defined by Diagnostic and Statis-
tical Manual of Mental Disorders (DSM-IV), 3) they had
not been suffering from an acute attack of psychiatric ill-
ness during the past year, and 4) their drug regimen had
not been changed in the past 6 months as evident from
their medical files. Patients who had the following char-
acteristics were excluded from the study: 1) newly diag-
nosed patients and 2) patients who were not on any
antipsychotic medication.
A convenience, non-probability sampling method was
used. To collect the sample, the researchers visited and
stayed 4 weeks in each center and collected data from
patients who met the inclusion criteria. In order to esti-
mate with sufficient precision the prescribing pattern,particularly, antipsychotic combination, we hypothesized
a worst-case scenario level of antipsychotic combination
of about 70%, to be estimated with a 95% confidence
interval of 15 percentage points. Therefore, we needed a
sample size of at least 134 patients. The final sample col-
lected during the study period was 250 clients. We de-
veloped data collection forms to cover all data items
needed. The form covered the following areas: socio-
demographic variables, psychiatric history, antipsychotic
medication currently being used, and history of psychi-
atric hospitalization. Before commencing the study, the
data collection form was modified by the researchers
and the modified version was reviewed by experts to en-
sure content and construct validity. Data from the pre-
test evaluation were not included in the final analysis.
Focus group discussions were continuously held be-
tween research team to identify any problems in data
collection or interpretation of definitions or application
of study criteria.
Approval to perform the study was obtained from the
Palestinian ministry of health, the college of Graduate
Studies at An-Najah national University and the Institu-
tional Review Boards (IRB) committee at An-Najah
National University. Written consent was obtained from
all participants.Tested variables
Chlorpromazine dose equivalencies (CPZeq)
The CPZeq is a measure of the relative antipsychotic
potencies of neuroleptics. They are generally expressed as
a ratio, relative to the arbitrary value of 1, which corre-
sponds to the antipsychotic effects of chlorpromazine. The
daily dose of antipsychotic medication prescribed to each
patient was converted to milligram equivalents of chlor-
promazine according to conversion factors derived from
the literature [11,12]. Total CPZeq was constructed by
calculating a total daily dose of each antipsychotic listed in
the medical file. Then each converted antipsychotic-
specific CPZeq amount is added to arrive at a total dose.
A maintenance dose of total CPZeq in the range of 300 –
600 mg is considered optimum.Antipsychotic combination
The operational definition of antipsychotic combination
is the use of two or more antipsychotic drugs while that
of monotherapy is the use of one antipsychotic drug. In
this study, since no changes were made in the thera-
peutic regimen of all clients, then no clients were in the
transitional period of changing or switching from one
antipsychotic to another. Therefore, clients who were on
combination therapy were actually on 2 or more medica-
tions and were not in a transitional phase of discontinu-
ation of one drug and an initiation of another drug.
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The Positive and Negative Syndrome Scale (PANSS)
which was published in 1987 [13,14] is widely used in
the study of antipsychotic therapy. The PANSS consists of
three sections: positive symptoms (7 items); negative symp-
toms (7 items); and general psychopathology (14 items).
Each item has a score from 1 – 7 with the highest scores
representing the highest severity. For each section, the total
score was calculated by summing the scores for all items in
that section. The interview with the clients to assess
PANSS was carried out by the author. The author (mental
health specialist) was trained on PANSS before the start of
the study. Each interview took 30 – 35 minutes.
Conformance indicators
In order to construct the indicators of conformance, we
reviewed several updated guidelines regarding recommen-
dations for maintenance pharmacological treatment of
schizophrenia [9,10]. We identified two major recommen-
dations that could be evaluated using a cross-sectional
medical chart review, and for which the required informa-
tion was available in the medical records.
I. The first conformance indicator recommends that
monotherapy is the preferred and evidence based
choice while combination therapy lacks evidence
and support. Our cross sectional methodology could
not be used to provide information on whether
patients were undergoing a trial of second
alternative antipsychotic drug (switching) or not.
However, we assumed that all patients were not
undergoing switching because their medications
have been constant since more than six months.
Therefore, we drafted a conformance indicator that
examined whether patients were receiving one or
combination.
II. The second conformance indicator recommends that
the maintenance dosage of antipsychotic medication
be in the range of 300 – 600 mg CPZeq per day.
Since all patients in the study sample had been ill for
a long time and their medications had not been
changed since the past six months, we assumed that
most patients were on maintenance doses and
created a conformance indicator that assessed
whether the antipsychotic dosages prescribed for
patients were between 300–600 mg CPZeq/day.
Cost of antipsychotic regimen
The total annual cost for antipsychotic treatment for each
patient was calculated in United State Dollar (1 USD = 3.7
New Israeli Shekel (NIS) at the time of the study).
The cost of each antipsychotic drug per dose per
unit was obtained from the Ministry of Health (personal
communication).Data analysis
Descriptive statistics for all study variables were com-
puted. These descriptive statistics included frequencies
and percentages for all categorical variables in addition
to means, standard deviations and ranges for all nor-
mally distributed continuous variables while median and
inter quartile range (Q1-Q3) for continuous variables
that were not normally distributed. Variables were tested
for normality using the Kolmogorov– Smirnov test.
Non-parametric binomial t-test was used to test the
difference in the prevalence of antipsychotic combin-
ation obtained in this study with those published else-
where. Statistical significance for intergroup differences
was assessed by the Student’s t-test for continuous vari-
ables. Univariate analysis and multiple logistic regression
was used to find significant factors associated with anti-
psychotic combination.
All statistical analyses were conducted using Statis-
tical Package for Social Sciences SPSS (PASW version
18.0; IBM, Somers, NY) statistical packages for Win-
dows. The conventional 5 percent significance level was
used throughout the study.
Results
General characteristics of the study sample
During the study period, 250 patients met the inclusion
criteria and were included in the study. The study sam-
ple represents approximately one third of patients with
schizophrenia attending the primary governmental psy-
chiatric clinics in north Palestine. The largest clinic in
terms of number of schizophrenic patients attending the
clinic on regular basis is the one in Nablus with approxi-
mately 350 patients followed by the ones in Tulkaram,
Jenin and Qalqilia with approximately 80 – 120 patients
each. The fact that schizophrenia patients have to attend
the psychiatric clinic at least once monthly to get their
antipsychotic medications made all patients at equal
chance of being seen and included in the study since the
authors spent one month in each clinic. It is noteworthy,
that most attendants to psychiatric primary healthcare
centers in north Palestine were male patients who mostly
visit the clinic in regular basis for evaluation and to obtain
medications. Patients not included in the study were
either unwilling to expose their illness to researchers or
were in a hurry and did not want to participate. Aside
from the above reasons, there is a small percentage of pa-
tients who does not usually show at the clinics regularly.
For the 250 clients studied, medical files were complete
for antipsychotic medications and their doses. However,
clinical data pertaining to psychiatric episodes, psychiatric
hospitalizations, co-morbid diseases and duration of psy-
chiatric illness were frequently missing.
The study sample included 68 (27.2%) female and 182
(72.8%) male clients. The mean age of the clients was
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difference in age was found between male and female
clients (40.3 ± 12.4 for females versus 42.5 ± 11.5 years
for males; p=0.2). The median duration of illness was 15
(Q1 – Q3: 9 – 20) years. The median number of psychi-
atric hospitalization of the clients during their lifetime
was 1 (Q1 – Q3: 0 – 2). Basic demographic and clinical
characteristics of the clients are shown in Table 1.
Medications used by the study sample
There were 406 prescriptions of antipsychotic drugs for
the study sample with a mean of 1.6 ± 0.7 (95% CI: 1.5 –
1.7) antipsychotic drug per patient. The antipsychotics
were mainly from FGA type (348, 85.7%) The most com-
mon antipsychotic medication used was chlorpromazine
tablet (128; 31.5%), followed by fluphenazine IM depotTable 1 General characteristics of the study sample





Age (years) 41.9± 11.8
Age category
-Less than 30 43 (17.2%)
-30 – 40 76 (30.4%)
-40 – 50 80 (32%)





-School education or less 213 (85.2%)








-Not working 219 (87.6%)
-Working 31 (12.4%)
Duration of psychiatric illness (years) 15 (Q1 – Q3: 9 – 20)
- ≤ 10 years 89 (35.6%)
- > 10 years 161 (64.4%)
Number of psychiatric hospitalization 1 (Q1 – Q3: 0 – 2)
Abbreviations: Q1–Q3 lower quartile–upper quartile, SD standard deviation.injection (125; 30.8%), haloperidol tablet (74; 18.2%), clo-
zapine tablet (35, 8.6%), olanzapine tablet (15, 3.7%),
haloperidol decanoate (11, 2.7%), risperidone tablet (8,
2%), trifluperazine tablet (7, 1.7%), thioridazine tablet
(1, 0.2%) and zuclopenthixol depot (2, 0.5%).
The total number of adjuvant medications used was 249
with an average of 1 ± 0.7 (95% CI: 0.9 – 1.1) medication
per patient. The most common adjuvant medications used
by the clients were: the anticholinergic/antiparkinsonian
drug, trihexyphenidyl (177; 71.1%) followed by antidepres-
sants (29; 11.7%) and mood stabilizers (26; 10.4%) and
benzodiazepines (anxiolytics) (17; 6.8%).Conformance to prescribing indicators
Antipsychotic combination
One hundred and twenty four clients (49.6%) were using
antipsychotic while the monotherapy while the remaining
clients were using antipsychotic combination. The various
antipsychotic combinations are shown in Table 2. The
most common combination was “FGA + FGA” (78/250;
31.8%) followed by “FGA + FGA + FGA” (24/250; 9.6%)
and “FGA + SGA” (17; 6.8%).
Analysis of cost indicated that the average annual cost
of antipsychotic medications was 229 ± 202 USD per cli-
ent (minimum: 48.7; maximum: 1168 USD). The average
annual cost in USD per client was greater but not sig-
nificantly different between clients on monotherapy ver-
sus those on antipsychotic combination (217 ± 200.7
USD for monotherapy versus 240.6 ±203.5 USD for
combination therapy; p=0.4).
One hundred and twenty two clients out of 250 in-
cluded clients in the study agreed to undergo the PANSS
test. Of the 122 clients, 32 (26.2%) were female and 90
(73.8%) were male patients. The mean age of the patients
was 41.5 ± 10.3 [95% CI: 39.7 – 43.4; range: 16 – 66] years.
No significant difference was observed in age or gender
distribution between patients who did and those who didTable 2 Types of antipsychotic regimens used in the
treatment of schizophrenia
Category Frequency (%)
One SGA 32 (12.8)
SGA + SGA 1 (0.4)
SGA + SGA + FGA 1 (0.4)
SGA + FGA 17 (6.8)
SGA + FGA + FGA 4 (1.6%)
One FGA 92 (36.8)
FGA + FGA 78 (31.2)
FGA + FGA + FGA 24 (9.6)
Total 250 (100)
Abbreviations: FGA First Generation Antipsychotics, SGA Second
Generation Antipsychotic.
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For the 122 patients, the average number of antipsychotic
medications used was 1.7 ± 0.7 (95% CI: 1.6 – 1.9),
mean CPZeq dose was 455.3 ± 283.4 (95% CI: 404.5 –
506.1), and 65 (53.3%) were receiving antipsychotic
combination. Again, no significant difference in anti-
psychotic medications was observed between those who
did and those who did not undergo the PANSS test. For
patients with monotherapy, the means ± SD of positive,
negative and psychopathology symptoms score were
20.8 ± 3.1; 19.7 ± 3.8 and 44.1 ± 6.3 respectively. For
patients with combination therapy, the means ± SD of
positive, negative and psychopathology symptoms score
were 21.5 ± 4; 21.2 ± 4.5 and 45.1 ± 7.8 respectively.
There was no significant difference in positive (p=0.3),
negative (p=0.06) and psychopathology symptoms (p=0.5)
scores between clients on monotherapy and combination
therapy.Antipsychotic maintenance dose
The average CPZeq dose measured in mg for the 250
clients was 436.9 ± 257.6 (95% CI: 403 – 471). No sig-
nificant difference was found in CPZeq dose between
male and female clients (386.8 ± 247.7 mg for females
versus 455.5 ± 283.7 mg; p=0.63).
Categorization of CPZeq dose showed that 88 (35.2%)
clients were using sub-therapeutic doses (<300 mg
CPZeq), 105 (42%) were using optimum dose (300 –
600 mg CPZeq) and 57 (22.8%) were using supra thera-
peutic doses (> 600 mg CPZeq). Only 7 (2.8%) clients
were using supra-maximal dose (CPZeq>1000 mg). Cli-
ents on antipsychotic combination had a mean CPZeq
of 614.3 ± 267.1 (95% CI: 567.2 – 661.4 mg) while those
on monotherapy had a mean CPZeq of 256.6 ±127.5
(95% CI 233.9 – 279.3 mg) (p <0.01).Factors associated with prescribing antipsychotic
combination
Univariate analysis for antipsychotic combinations is
shown in Table 3. It showed that antipsychotic combin-
ation was a significant associated with the following vari-
ables: smoking (p=0.04), duration of psychiatric illness >
10 years (p=0.01), number of psychiatric hospitalization ≥
2 (p=0.001), use of depot antipsychotic agents (p<0.01),
use of anticholinergics (p<0.01), and use of high CPZeq
dose (p<0.01). Table 4 shows the multivariate logistic re-
gression analysis of factors related to antipsychotic com-
bination. All included variables had a significant p-value in
the univariate analysis between antipsychotic combination
and monotherapy groups. Results showed that the follow-
ing variables are significant predictors of antipsychotic
combination: use of depot medications, use of anticholin-
ergic agents and use of high CPZeq dose.Discussion
This study investigated conformance with antipsychotic
treatment guidelines among schizophrenic patients at-
tending governmental primary psychiatric healthcare cen-
ters in northern West-Bank of Palestine. We developed 2
indicators to measure conformance and appropriateness
of antipsychotic prescribing with treatment guidelines for
patients with schizophrenia: (1) the antipsychotic mono-
therapy and (2) antipsychotic maintenance dosing. Our
study showed that antipsychotic prescribing was not in
conformance with international guidelines with respect to
maintenance dose and combination therapy.
In our study, the prevalence of antipsychotic drug com-
bination was significantly higher than those reported in
many other countries. A study in South Africa reported a
prevalence of 28.6% of antipsychotic polypharmacy while a
study in Nigeria reported a prevalence of 92% of anti-
psychotic combination [15,16]. Studies in USA and Canada
reported prevalence of antipsychotic combination similar to
that in South Africa (27.5% and 25.7% respectively) [17,18].
Reports in Asia also showed low (< 31%) prevalence of
antipsychotic combination [19,20]. Discrepancies in preva-
lence of antipsychotic combination across studies may be
accounted for by differences in the definition of anti-
psychotic combination. Although most studies defined
combination as any time with more than one antipsychotic
[21,22], others have set specific time requirements, such as
at least 14 days of concurrent antipsychotic use [23]. Other
potential reasons for variations in the prevalence of anti-
psychotic combination across studies include availability
and type of medical insurance for schizophrenia patients as
well as clinical experience and knowledge of psycho-
pharmacology by medical practitioners [24].
Our results showed that antipsychotic combination
was not associated with better clinical outcome. Similar
findings were obtained by other studies. A study looking
at combination of FGA and SGA found that there was
little evidence of an improvement in outcome and there
was a significant increase in adverse effect burden [25].
Another study found that use of combination anti-
psychotic agents was associated with an increased inci-
dence of metabolic syndrome [26]. Honer et al. (2006)
observed that antipsychotic polypharmacy (APP) led to
greater worsening on verbal memory compared to anti-
psychotic monotherapy (APM) [27]. A double blind
randomized control trial found no significant change in
symptoms observed with APM augmentation on Brief
Psychiatric Rating Scale (BPRS) [28]. On the contrary,
an observational study of amisulpride added to clozapine
for psychosis unresponsive to clozapine monotherapy
observed that clozapine combination led to greater im-
provement in symptoms on BPRS [29].
In our study, antipsychotic combination was not signifi-
cantly associated with patient’s gender. This is contrary to
Table 3 Univariate analysis (binary logistic regression) for prescribing monotherapy versus combination therapy
Variable Reference category β p-value Odds ratio with 95% CI
Gender Male 0.43 0.14 1.5 (0.88 – 2.7)
Age Continuous variable 0.008 0.5 1.0 (1.0-1.03)
Education School education 0.338 0.4 1.4 (0.7-2.8)
Marital status Single −0.2 0.4 0.8 (0.5-1.3)
Smoking Not smoking 0.45 0.04 1.7 (1.02-2.9)
Occupation Not working 0.055 0.9 1.1 (0.5-2.2)
Waist circumferences Normal WC −0.16 0.5 0.9 (0.52-1.4)
Duration of psychiatric illness < 10 years 0.7 0.01 2 (1.2-3.4)
Number of hospitalization < 2 1.02 0.001 2.8 (1.5-5.1)
Family history of DM No family history −0.16 0.53 0.9 (0.42-1.4)
Depot No depot 2.0 < 0.001 7.4 (4.2-12.9)
Anticholinergic No anticholinergics 1.9 <0.001 6.7 (3.5-12.8)
SGA No SGA −0.4 0.2 0.7 (0.4-1.2)
CPZeq Continuous variable −5.5 <0.001 1.01 (1.0 – 1.01)
Abbreviations: CI confidence interval, β coefficient of predictor variables, DM diabetes mellitus, SGA Second Generation Antipsychotic, CPZeq Chlorpromazine
Dose Equivalencies.
Table 4 Multivariate logistic regression for variables
significantly associated with prescribing antipsychotic
combination
Variable B p-value Odds ratio
with 95% CI
Smoker 0.181 0.661 1.199 (0.534-2.692)
Duration of psychiatric
illness > 10 years
−0.435- 0.327 0.647 (0.271-1.545)
Number of psychiatric
hospitalization ≥ 2
0.614 0.229 1.849 (0.679-5.034)
Use of depot antipsychotic
agents
1.270 0.002 3.560 (1.572-8.061)
Use of anticholinergic
agents
1.336 0.005 3.804 (1.511-9.578)
Total CPZeq 0.010 <0.001 1.010 (1.007-1.013)
Abbreviations: CI confidence interval, β coefficient of predictor variables, CPZeq
Chlorpromazine Dose Equivalencies.
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crease in antipsychotic combination among male pa-
tients [23,30]. Equivocally, Chalks et al. (2006) reported
an increase in antipsychotic combination among female
patients [31]. Our finding regarding the association be-
tween anti cholinergic agents use and antipsychotic com-
bination is consistent with previous studies [22,32,33].
Antipsychotic combination is expected to be associated
with higher CPZeq effects which explains the significant
association between antipsychotic combination and use of
anticholinergic agents [22].
Our finding concerning the association of antipsychotic
combination with depot antipsychotic medication was
also proofed by other studies [12,22]. Treatment guide-
lines do not have particular recommendations regard-
ing use of depot antipsychotic medications. It could be
argued that due to limited mental health staff and ser-
vices in many primary healthcare clinics in Palestine,
physician and patients’ families prefer depot medica-
tions to minimize visits and avoid the daily burden on
these clinics.
In our study, only 43% of patients received the
recommended antipsychotic maintenance dose of 300–
600 mg CPZ equivalents, while 26% received doses
below the recommended doses and 32% received above
the recommended doses. Similar results were reported
in other studies [34,35]. Kreyenbuhl et al., (2007) ob-
served that dosages prescribed for patients receiving
polypharmacy were the same or modestly higher than
those prescribed for patients receiving monotherapy
[30]. Another study observed that CPZeq dose of pa-
tients on APP was significantly higher than those on
APM which was in accordance with our findings [36].37 Also Barnes TR 2011 found that polypharmacy is a
major contributor to high dose prescribing [37].
Strength and limitations of the study
To the best of author‘s’ knowledge, this study is consid-
ered the first of its type and one of the few about mental
health practices in Palestine. Several healthcare centers
were included in the study and a relatively large sample
size was obtained. However, our study has some limita-
tions. First, the Palestinian culture and lack of psychi-
atric hospitals in north Palestine has affected some
characteristics of the study sample. For example, female
patients were under-represented in the sample possibly
because families of female psychiatric patients seek private
health services rather than governmental public healthcare
services. Second, there were missing information in the
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pitalization, duration of psychiatric illness and co-morbid
diseases. The sub-sample which was tested for the PANSS
test is believed to be representative of the total sample
since no significant difference in demographic and medi-
cation characteristics was observed between the sub-
sample and the total sample. Third, the cross sectional
design of the study limits interpretation of the results. The
researchers stayed in each clinic for one month to make
sure that all psychiatric clients have equal chance of being
interviewed and included in the study. Despite this, the
convenience sampling is a limitation and might possibly
affect the representative nature of the sample. Fourth,
most variables used in this study relied on information
obtained from medical files. Finally, lack of a side effect
assessment of study participants is also a limitation.
Conclusion
Although, this study showed that antipsychotic combin-
ation is common, further studies are required to investi-
gate the real intentions of the physician and whether
prescribing of the combination is preceded by failure
trails of monotherapy. Furthermore, more research is re-
quired to characterize the benefits and risks of anti-
psychotic combinations using different clinical tools for
psychiatric assessment.
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